TNGX FY 2020 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-68.9% YoY

Gross Profit

$6M78.8% margin

Operating Income

-$52M-681.8% margin

Net Income

-$52M-678.8% margin

EPS (Diluted)

$-1.62

Cash Flow

Operating Cash Flow

$70M

Free Cash Flow

$69M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$207M

Total Liabilities

$169M

Stockholders' Equity

$39M

Cash & Equivalents

$28M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$25M	-68.9%
Gross Profit	$6M	-$8M	+179.1%
Operating Income	-$52M	-$15M	-244.3%
Net Income	-$52M	-$14M	-268.7%